DUBLIN--(BUSINESS WIRE)--Mallinckrodt (NYSE: MNK) today announced that it was granted a patent from the United States Patent and Trademark Office which contains composition claims directed to unique design, formulation, pharmacokinetic, and release characteristics of XARTEMISTM XR. XARTEMIS XR (formerly known as MNK-795) is an investigational extended-release oral formulation of oxycodone and acetaminophen that has been studied with twice daily dosing for the management of acute pain in a post-surgical model. If approved, XARTEMIS XR will be the first oxycodone and acetaminophen combination medication specifically designed with immediate- and extended-release components. The patent, U.S. Patent Number 8,658,631, was issued on February 25, 2014.
Help employers find you! Check out all the jobs and post your resume.
